{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:36:55Z","timestamp":1790217415794,"version":"4.1.0"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Prospective long-term data after retinopathy of prematurity (ROP) treatment with anti\u2013vascular endothelial growth factor injections vs laser therapy are scarce. The FIREFLEYE (Aflibercept for ROP IVT Injection vs Laser Therapy) next trial is prospectively evaluating the long-term efficacy and safety outcomes following ROP treatment with intravitreal aflibercept vs laser therapy.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate 2-year ophthalmic and safety outcomes after 0.4-mg aflibercept injection or laser therapy in the 24-week randomized (2:1) FIREFLEYE trial (FIREFLEYE outcomes previously reported).<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This prospective nonrandomized controlled trial performed in 24 countries in Asia, Europe, and South America (2020-2025) follows up participants treated in the FIREFLEYE randomized clinical trial (2019-2021) through 5 years of age. Participants included children born very or extremely preterm (gestational age \u226432 weeks) or with very or extremely low birth weight (\u22641500 g) who were previously treated with a 0.4-mg injection of aflibercept compared with laser therapy for severe acute-phase ROP. Data for the present interim analysis were acquired from March 18, 2020, to July 25, 2022.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Complications of ROP treated at investigator discretion (no study treatment).<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Efficacy end points included ROP status, unfavorable structural outcomes, ROP recurrence, treatment for ROP complications, completion of vascularization, and visual function. Safety end points included adverse events and growth and neurodevelopmental outcomes.<\/jats:p><\/jats:sec>Results<\/jats:title>Overall, 100 children were enrolled (median gestational age, 26 [range, 23-31] weeks; 53 boys and 47 girls). Of these, 21 were Asian, 2 were Black, 75 were White, and 2 were of more than 1 race. At 2 years of age, 61 of 63 children (96.8%) in the aflibercept group vs 30 of 32 (93.8%) in the laser group had no ROP. Through 2 years of age, 62 of 66 (93.9%) in the aflibercept group and 32 of 34 (94.1%) in the laser group had no unfavorable structural outcomes. No new retinal detachment occurred during the study. Four children in the aflibercept group (6.1%) were treated for ROP complications before 1 year of age (2 had preexisting end-stage disease and total retinal detachment; 1 had reactivated plus disease; and 1 had recurrent retinal neovascularization not further specified). Most children were able to fix and follow a 5-cm toy (aflibercept group, 118 of 122 eyes [96.7%] among 63 children; laser group, 62 of 63 eyes [98.4%] among 33 children). High myopia was present in 9 of 115 eyes (7.8%) among 5 children in the aflibercept group and 13 of 60 eyes (21.7%) among 9 children in the laser group. No relevant differences in growth and neurodevelopmental outcomes by Bayley Scales of Infant and Toddler Development, Third Edition and Vineland Adaptive Behavior Scales, Second Edition were identified.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this nonrandomized follow-up of a randomized clinical trial comparing treatment of severe acute-phase ROP with 0.4-mg injection of aflibercept and laser, disease control was stable and visual function was appropriate in children through 2 years of age. No adverse effects on safety, including growth and neurodevelopment, were identified. These findings provide clinically relevant long-term information on intravitreal aflibercept injection therapy for ROP.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT04015180<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.8383","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T15:35:30Z","timestamp":1714491330000},"page":"e248383","source":"Crossref","is-referenced-by-count":31,"title":["Intravitreal Aflibercept vs Laser Therapy for Retinopathy of Prematurity"],"prefix":"10.1001","volume":"7","author":[{"given":"Andreas","family":"Stahl","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University Medicine Greifswald, Greifswald, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiko","family":"Nakanishi","sequence":"additional","affiliation":[{"name":"Research and Development Center for New Medical Frontiers, Division of Neonatal Intensive Care Medicine, Department of Advanced Medicine, Kitasato University School of Medicine, Sagamihara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Lepore","sequence":"additional","affiliation":[{"name":"Department of Geriatrics and Neuroscience, Catholic University of the Sacred Heart, A. Gemelli Foundation Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chi","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Azuma","sequence":"additional","affiliation":[{"name":"Medical Research Institute, Department of Developmental and Regenerative Biology, Tokyo Medical and Dental University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Jacas","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Hospital Universitari Vall d\u2019Hebron, Vall d\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Vitti","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Athanikar","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Chu","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Iveli","sequence":"additional","affiliation":[{"name":"Bayer AG, Wuppertal, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Bayer Inc, Mississauga, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Leal","sequence":"additional","affiliation":[{"name":"Bayer Consumer Care AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Schlief","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schmelter","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Miller","sequence":"additional","affiliation":[{"name":"Bayer Healthcare LLC, Whippany, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evra","family":"K\u00f6f\u00fcnc\u00fc","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair","family":"Fielder","sequence":"additional","affiliation":[{"name":"Department of Optometry and Visual Science, City, University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"FIREFLEYE next Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Larrea","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Delbeke","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilva","family":"de Moraes","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Regina","family":"Bentlin","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violeta","family":"Chernodrinska","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Grupcheva","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliyana","family":"Dimitrova","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasil","family":"Marinov","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Kovacova","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juraj","family":"Timkovic","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Asproudis","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathi","family":"Kouri","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asimina","family":"Mataftsi","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erzsebet","family":"Princzkel","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Leiba","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Buzzonetti","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Cagini","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Lepore","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Gabriella","family":"Osnaghi","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Arima","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Hayashi","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Kiyota","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kondo","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Kusaka","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Miyazato","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichiro","family":"Noda","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunobu","family":"Saneyoshi","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuju","family":"Sekiryu","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Tachikawa","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nor Akmal","family":"Bahari","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"de Geus","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Kerkhoff","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Almeida","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Teixeira","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narcis","family":"Berlea","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Nicoara","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Gorelik","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyvgeny","family":"Sidorenko","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Trifanenkova","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin Huey","family":"Quek","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Tomcikova","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Young","family":"Kim","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Yong","family":"Lee","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Peralta Calvo","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Escudero G\u00f3mez","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Tejada Palacios","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Hellstr\u00f6m","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hung","family":"Lai","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiang-Ling","family":"Tsai","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikmet","family":"Basmak","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel","family":"Caliskan Kadayifcilar","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammet","family":"Erol","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sengul","family":"Ozdek","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice Tugba","family":"Atalay","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep","family":"Canserver","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emine","family":"Sukgen","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Painter","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergii","family":"Katsan","sequence":"additional","affiliation":[{"name":"for the FIREFLEYE next Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"issue":"6","key":"zoi240306r1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-3061","article-title":"Screening examination of premature infants for retinopathy of prematurity.","volume":"142","author":"Fierson","year":"2018","journal-title":"Pediatrics"},{"issue":"12","key":"zoi240306r2","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity randomized trial.","volume":"121","author":"Early Treatment for Retinopathy of Prematurity Cooperative Group","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"zoi240306r3","first-page":"233","article-title":"Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial.","volume":"102","author":"Good","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"12","key":"zoi240306r4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225643","article-title":"Development of refractive error in children treated for retinopathy of prematurity with anti\u2013vascular endothelial growth factor (anti-VEGF) agents: a meta-analysis and systematic review.","volume":"14","author":"Tan","year":"2019","journal-title":"PLoS One"},{"issue":"10","key":"zoi240306r8","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/S2352-4642(21)00195-4","article-title":"2-Year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial.","volume":"5","author":"Marlow","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"issue":"4","key":"zoi240306r9","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1001\/jama.2022.10564","article-title":"Effect of intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity: the FIREFLEYE randomized clinical trial.","volume":"328","author":"Stahl","year":"2022","journal-title":"JAMA"},{"issue":"4","key":"zoi240306r10","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s00417-022-05900-6","article-title":"Final 4-year results of the RAINBOW real-world study: intravitreal aflibercept dosing regimens in France in treatment-na\u00efve patients with neovascular age-related macular degeneration.","volume":"261","author":"Cohen","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"zoi240306r11","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"zoi240306r12","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"issue":"10208","key":"zoi240306r13","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial.","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"zoi240306r15","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity.","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"issue":"2","key":"zoi240306r16","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-3537","article-title":"Neurodevelopmental outcomes of preterm infants with retinopathy of prematurity by treatment.","volume":"144","author":"Natarajan","year":"2019","journal-title":"Pediatrics"},{"issue":"3","key":"zoi240306r17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0230678","article-title":"Neurodevelopmental outcomes following intravitreal bevacizumab injection in Japanese preterm infants with type 1 retinopathy of prematurity.","volume":"15","author":"Arima","year":"2020","journal-title":"PLoS One"},{"issue":"2","key":"zoi240306r18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/IAE.0b013e318275394a","article-title":"Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up.","volume":"33","author":"Mart\u00ednez-Castellanos","year":"2013","journal-title":"Retina"},{"issue":"1","key":"zoi240306r19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148019","article-title":"Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment.","volume":"11","author":"Lien","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"zoi240306r20","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-0056A","article-title":"Neurodevelopmental outcomes of preterm infants with retinopathy of prematurity by treatment.","volume":"145","author":"Rodriguez","year":"2020","journal-title":"Pediatrics"},{"issue":"1","key":"zoi240306r21","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1111\/aos.v100.1","article-title":"Ranibizumab in retinopathy of prematurity - one-year follow-up of ophthalmic outcomes and two-year follow-up of neurodevelopmental outcomes from the CARE-ROP study.","volume":"100","author":"Stahl","year":"2022","journal-title":"Acta Ophthalmol"},{"issue":"20","key":"zoi240306r22","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"7","key":"zoi240306r24","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The International Classification of Retinopathy of Prematurity revisited.","volume":"123","author":"International Committee for the Classification of Retinopathy of Prematurity","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"zoi240306r25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40942-018-0125-z","article-title":"Incidence and risk factors for retinopathy of prematurity: a retrospective cohort study.","volume":"4","author":"Freitas","year":"2018","journal-title":"Int J Retina Vitreous"},{"issue":"3","key":"zoi240306r26","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1001\/jamaophthalmol.2018.5984","article-title":"Development of a retinopathy of prematurity activity scale and clinical outcome measures for use in clinical trials.","volume":"137","author":"Smith","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"zoi240306r5","unstructured":"Bayer AG. Eylea: summary of product characteristics. 2023. Accessed October 16, 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/eylea-epar-product-information_en.pdf"},{"key":"zoi240306r6","unstructured":"Regeneron Pharmaceuticals, Inc. Eylea: prescribing information. 2023. Accessed October 16, 2023. https:\/\/www.regeneron.com\/downloads\/eylea_fpi.pdf"},{"key":"zoi240306r7","unstructured":"Novartis Europharm Limited. Lucentis: summary of product characteristics. 2023. Accessed October 16, 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lucentis-epar-product-information_en.pdf"},{"key":"zoi240306r14","unstructured":"Study to assess the efficacy, safety, and tolerability of intravitreal aflibercept compared to laser photocoagulation in patients with retinopathy of prematurity (BUTTERFLEYE). ClinicalTrials.gov identifier: NCT04101721. Updated July 20, 2023. Accessed October 16, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04101721"},{"key":"zoi240306r23","unstructured":"Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice. Accessed March 26, 2024. https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2818071\/stahl_2024_oi_240306_1713448558.80848.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T15:35:39Z","timestamp":1714491339000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2818071"}},"subtitle":["Two-Year Efficacy and Safety Outcomes in the Nonrandomized Controlled Trial FIREFLEYE next"],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.8383","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,30]]}}}